No effect of vitamin D administration plus dietary intervention on emerging cardiovascular risk factors in patients with metabolic syndrome
Background: Patients with metabolic syndrome (MetS) have low serum 25-hydroxyvitamin D (25(OH)VitD) levels. Low 25(OH)VitD has been associated with several emerging cardiovascular disease (CVD) risk factors, while VitD administration may ameliorate them. Aim: To study the effect of 25(OH)VitD supple...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2019-06-01
|
| Series: | Journal of Nutrition & Intermediary Metabolism |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2352385918300719 |
| _version_ | 1811280704469729280 |
|---|---|
| author | Stefania E. Makariou Moses Elisaf Anna Challa Constantinos C. Tellis Alexandros D. Tselepis Evangelos N. Liberopoulos |
| author_facet | Stefania E. Makariou Moses Elisaf Anna Challa Constantinos C. Tellis Alexandros D. Tselepis Evangelos N. Liberopoulos |
| author_sort | Stefania E. Makariou |
| collection | DOAJ |
| description | Background: Patients with metabolic syndrome (MetS) have low serum 25-hydroxyvitamin D (25(OH)VitD) levels. Low 25(OH)VitD has been associated with several emerging cardiovascular disease (CVD) risk factors, while VitD administration may ameliorate them. Aim: To study the effect of 25(OH)VitD supplementation plus dietary instructions on novel CVD risk factors in MetS patients. Methods: This is a pre-specified analysis of a previously published study. Patients with MetS (n = 50, 52 ± 10 years) were given dietary instructions and were randomized to receive either 25(OH)VitD, 2.000 IU/day p.o. (Suppl group) or nothing (No-Suppl group). Serum 25(OH)VitD, small dense low-density lipoprotein cholesterol (sdLDL), as well as lipoprotein-associated phospholipase A2 (LpPLA2) activity, leptin and adiponectin levels were measured at baseline and 3 months later. Results: In the Suppl group 25(OH)VitD levels increased by 90% [from 16.1 (3.3–35.1) to 30.6 (8.4–67.6) ng/mL, p = 0.001] and by 33.3% [from 9.9 (4.0–39.6) to 13.2 (3.5–36.8) ng/mL, p = NS] in the No-Suppl group. sdLDL serum levels, mean LDL size, LpPLA2 activity, leptin, adiponectin concentration and leptin to adiponectin ratio did not change significantly in both groups. Conclusion: In this small study the administration of 25(OH)VitD plus dietary intervention in patients with MetS were not associated with any significant change in various emerging CVD risk factors. (NCT01237769 ClinicalTrials.gov). Keywords: Metabolic syndrome, 25(OH)VitD, Small dense low-density lipoprotein cholesterol, Lipoprotein-associated phospholipase A2, Leptin, Adiponectin |
| first_indexed | 2024-04-13T01:20:41Z |
| format | Article |
| id | doaj.art-2028fa89bd494b6e8000c1f0beddbe21 |
| institution | Directory Open Access Journal |
| issn | 2352-3859 |
| language | English |
| last_indexed | 2024-04-13T01:20:41Z |
| publishDate | 2019-06-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Journal of Nutrition & Intermediary Metabolism |
| spelling | doaj.art-2028fa89bd494b6e8000c1f0beddbe212022-12-22T03:08:47ZengElsevierJournal of Nutrition & Intermediary Metabolism2352-38592019-06-0116No effect of vitamin D administration plus dietary intervention on emerging cardiovascular risk factors in patients with metabolic syndromeStefania E. Makariou0Moses Elisaf1Anna Challa2Constantinos C. Tellis3Alexandros D. Tselepis4Evangelos N. Liberopoulos5Child Health Department, Medical School, University of Ioannina, 45110, Ioannina, GreeceDepartment of Internal Medicine, Medical School, University of Ioannina, 45110, Ioannina, Greece; Corresponding author.Child Health Department, Medical School, University of Ioannina, 45110, Ioannina, GreeceAtherothrombosis Research Centre/Laboratory of Biochemistry, Department of Chemistry, University of Ioannina, 45110, Ioannina, GreeceAtherothrombosis Research Centre/Laboratory of Biochemistry, Department of Chemistry, University of Ioannina, 45110, Ioannina, GreeceDepartment of Internal Medicine, Medical School, University of Ioannina, 45110, Ioannina, Greece; Corresponding author. Department of Internal Medicine, Faculty of Medicine, School of Health Sciences, University of Ioannina, Ioannina 45 110, Greece.Background: Patients with metabolic syndrome (MetS) have low serum 25-hydroxyvitamin D (25(OH)VitD) levels. Low 25(OH)VitD has been associated with several emerging cardiovascular disease (CVD) risk factors, while VitD administration may ameliorate them. Aim: To study the effect of 25(OH)VitD supplementation plus dietary instructions on novel CVD risk factors in MetS patients. Methods: This is a pre-specified analysis of a previously published study. Patients with MetS (n = 50, 52 ± 10 years) were given dietary instructions and were randomized to receive either 25(OH)VitD, 2.000 IU/day p.o. (Suppl group) or nothing (No-Suppl group). Serum 25(OH)VitD, small dense low-density lipoprotein cholesterol (sdLDL), as well as lipoprotein-associated phospholipase A2 (LpPLA2) activity, leptin and adiponectin levels were measured at baseline and 3 months later. Results: In the Suppl group 25(OH)VitD levels increased by 90% [from 16.1 (3.3–35.1) to 30.6 (8.4–67.6) ng/mL, p = 0.001] and by 33.3% [from 9.9 (4.0–39.6) to 13.2 (3.5–36.8) ng/mL, p = NS] in the No-Suppl group. sdLDL serum levels, mean LDL size, LpPLA2 activity, leptin, adiponectin concentration and leptin to adiponectin ratio did not change significantly in both groups. Conclusion: In this small study the administration of 25(OH)VitD plus dietary intervention in patients with MetS were not associated with any significant change in various emerging CVD risk factors. (NCT01237769 ClinicalTrials.gov). Keywords: Metabolic syndrome, 25(OH)VitD, Small dense low-density lipoprotein cholesterol, Lipoprotein-associated phospholipase A2, Leptin, Adiponectinhttp://www.sciencedirect.com/science/article/pii/S2352385918300719 |
| spellingShingle | Stefania E. Makariou Moses Elisaf Anna Challa Constantinos C. Tellis Alexandros D. Tselepis Evangelos N. Liberopoulos No effect of vitamin D administration plus dietary intervention on emerging cardiovascular risk factors in patients with metabolic syndrome Journal of Nutrition & Intermediary Metabolism |
| title | No effect of vitamin D administration plus dietary intervention on emerging cardiovascular risk factors in patients with metabolic syndrome |
| title_full | No effect of vitamin D administration plus dietary intervention on emerging cardiovascular risk factors in patients with metabolic syndrome |
| title_fullStr | No effect of vitamin D administration plus dietary intervention on emerging cardiovascular risk factors in patients with metabolic syndrome |
| title_full_unstemmed | No effect of vitamin D administration plus dietary intervention on emerging cardiovascular risk factors in patients with metabolic syndrome |
| title_short | No effect of vitamin D administration plus dietary intervention on emerging cardiovascular risk factors in patients with metabolic syndrome |
| title_sort | no effect of vitamin d administration plus dietary intervention on emerging cardiovascular risk factors in patients with metabolic syndrome |
| url | http://www.sciencedirect.com/science/article/pii/S2352385918300719 |
| work_keys_str_mv | AT stefaniaemakariou noeffectofvitamindadministrationplusdietaryinterventiononemergingcardiovascularriskfactorsinpatientswithmetabolicsyndrome AT moseselisaf noeffectofvitamindadministrationplusdietaryinterventiononemergingcardiovascularriskfactorsinpatientswithmetabolicsyndrome AT annachalla noeffectofvitamindadministrationplusdietaryinterventiononemergingcardiovascularriskfactorsinpatientswithmetabolicsyndrome AT constantinosctellis noeffectofvitamindadministrationplusdietaryinterventiononemergingcardiovascularriskfactorsinpatientswithmetabolicsyndrome AT alexandrosdtselepis noeffectofvitamindadministrationplusdietaryinterventiononemergingcardiovascularriskfactorsinpatientswithmetabolicsyndrome AT evangelosnliberopoulos noeffectofvitamindadministrationplusdietaryinterventiononemergingcardiovascularriskfactorsinpatientswithmetabolicsyndrome |